BRIEF-Fennec Pharmaceuticals And Norgine Enter Into Exclusive Licensing Agreement To Commercialize Pedmarqsi In Europe, Australia, And New Zealand

Reuters03-18

March 17 (Reuters) - Fennec Pharmaceuticals Inc

* FENNEC PHARMACEUTICALS AND NORGINE ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE PEDMARQSI IN EUROPE, AUSTRALIA, AND NEW ZEALAND

* WILL RECEIVE EUR 40 MILLION IN UPFRONT AND UP TO EUR 210 MILLION IN ADDITIONAL COMMERCIAL AND REGULATORY MILESTONES,

* FENNEC - NORGINE WILL BE RESPONSIBLE FOR COMMERCIALIZATION ACTIVITIES IN LICENSED TERRITORIES AND WILL HOLD ALL MARKETING AUTHORIZATIONS THERE

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2420461754?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-18 09:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2420461754","market":"us","top_or_hot":-1,"title":"BRIEF-Fennec Pharmaceuticals And Norgine Enter Into Exclusive Licensing Agreement To Commercialize Pedmarqsi In Europe, Australia, And New Zealand","media":"Reuters","content":"<html><body><p>March 17 (Reuters) - Fennec Pharmaceuticals Inc</p><p> :</p><p>   * FENNEC PHARMACEUTICALS AND NORGINE ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE PEDMARQSI IN EUROPE, AUSTRALIA, AND NEW ZEALAND</p><p>   * WILL RECEIVE EUR 40 MILLION IN UPFRONT AND UP TO EUR 210 MILLION IN ADDITIONAL COMMERCIAL AND REGULATORY MILESTONES,</p><p>   * FENNEC - NORGINE WILL BE RESPONSIBLE FOR  COMMERCIALIZATION ACTIVITIES IN LICENSED TERRITORIES AND WILL HOLD ALL MARKETING AUTHORIZATIONS THERE</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Fennec Pharmaceuticals And Norgine Enter Into Exclusive Licensing Agreement To Commercialize Pedmarqsi In Europe, Australia, And New Zealand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Fennec Pharmaceuticals And Norgine Enter Into Exclusive Licensing Agreement To Commercialize Pedmarqsi In Europe, Australia, And New Zealand\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-18 09:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 17 (Reuters) - Fennec Pharmaceuticals Inc :   * FENNEC PHARMACEUTICALS AND NORGINE ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE PEDMARQSI IN EUROPE, AUSTRALIA, AND NEW ZEALAND   * ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FENC","symbol_name":"Fennec Pharmaceuticals Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2420461754","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2420461754","pubTimestamp":1710723707,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 17  - Fennec Pharmaceuticals Inc :   * FENNEC PHARMACEUTICALS AND NORGINE ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE PEDMARQSI IN EUROPE, AUSTRALIA, AND NEW ZEALAND   * WILL RECEIVE EUR 40 MILLION IN UPFRONT AND UP TO EUR 210 MILLION IN ADDITIONAL COMMERCIAL AND REGULATORY MILESTONES,   * FENNEC - NORGINE WILL BE RESPONSIBLE FOR  COMMERCIALIZATION ACTIVITIES IN LICENSED TERRITORIES AND WILL HOLD ALL MARKETING AUTHORIZATIONS THERESource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FENC":"Fennec Pharmaceuticals Inc.","BK4139":"生物科技"},"translate_title":"Fennec Pharmaceuticals和Norgine签订独家许可协议，在欧洲、澳大利亚和新西兰将Pedmarqsi商业化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FENC":0.9},"content_text":"March 17 (Reuters) - Fennec Pharmaceuticals Inc :   * FENNEC PHARMACEUTICALS AND NORGINE ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE PEDMARQSI IN EUROPE, AUSTRALIA, AND NEW ZEALAND   * WILL RECEIVE EUR 40 MILLION IN UPFRONT AND UP TO EUR 210 MILLION IN ADDITIONAL COMMERCIAL AND REGULATORY MILESTONES,   * FENNEC - NORGINE WILL BE RESPONSIBLE FOR  COMMERCIALIZATION ACTIVITIES IN LICENSED TERRITORIES AND WILL HOLD ALL MARKETING AUTHORIZATIONS THERESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2420461754"}